There are 412 resources available
Mentor guided discussion
Presenter: Sara Tolaney
Session: YO Clinical case discussion
Resources:
Webcast
Q&A and general discussion
Session: YO Clinical case discussion
Resources:
Webcast
6P - HbA1c as a prognostic biomarker in early breast cancer among patients without diabetes
Presenter: Jonas Holm
Session: Lunch and Poster Display session
7P - Trastuzumab deruxtecan (T-DXd) for advanced breast cancer (ABC) patients (pts), regardless of HER2 status: A phase II study with biomarkers analysis (DAISY) - update analysis with longer follow-up
Presenter: Veronique Dieras
Session: Lunch and Poster Display session
8P - Evaluating HER2DX pCR-Score and MRI response in predicting pathologic complete response (pCR) to anti-HER2 neoadjuvant chemotherapy (CT) in early-stage HER2-positive (HER2+) breast cancer (BC)
Presenter: Tomas Pascual
Session: Lunch and Poster Display session
10P - PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy: A biomarker study of the LORELEI trial
Presenter: Danai Fimereli
Session: Lunch and Poster Display session
11P - Influence of ctDNA variant allele frequency (VAF) on survival outcomes in metastatic breast cancer (MBC)
Presenter: Isabel Garcia-Fructuoso
Session: Lunch and Poster Display session
12P - Updated findings from the first prospective HER2DX clinical decision impact study on early-stage HER2-positive (HER2+) breast cancer (BC)
Presenter: Olga Martinez Saez
Session: Lunch and Poster Display session
13P - HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratification
Presenter: Rodrigo Sanchez Bayona
Session: Lunch and Poster Display session
14P - Assessing the predictive value of HER2DX pCR-score for pathologic complete response (pCR) in early-stage HER2-positive (HER2+) breast cancer (BC) under real-world conditions
Presenter: Olga Martinez Saez
Session: Lunch and Poster Display session